Literature DB >> 19015760

Surgical management and postoperative treatment of endometrial carcinoma.

Jason A Lachance, Christopher J Darus, Laurel W Rice.   

Abstract

Endometrial carcinoma affects over 40,000 American women annually, making it the most common gynecologic malignancy. Over 80% of disease is diagnosed in the early stages, resulting in a generally favorable prognosis for most patients. However, discrepancies still exist with regard to primary surgical management and postoperative adjuvant therapies directed at reducing recurrence rates and improving survival. In this review, we outline the surgical management of newly diagnosed disease and review the risk factors that guide clinicians in the recommendation for postoperative adjuvant therapy.

Entities:  

Keywords:  Chemotherapy; Endometrial cancer; Hysterectomy; Lymphadenectomy; Radiation

Year:  2008        PMID: 19015760      PMCID: PMC2582654     

Source DB:  PubMed          Journal:  Rev Obstet Gynecol        ISSN: 1941-2797


  49 in total

1.  Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy.

Authors:  J Fanning
Journal:  Gynecol Oncol       Date:  2001-08       Impact factor: 5.482

2.  Predictors of final histology in patients with endometrial cancer.

Authors:  Michael Frumovitz; Diljeet K Singh; Larissa Meyer; Daniel H Smith; Iris Wertheim; Ephraim Resnik; Diane C Bodurka
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

3.  The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.

Authors:  Laura J Havrilesky; Janiel M Cragun; Brian Calingaert; Angeles Alvarez Secord; Fidel A Valea; Daniel L Clarke-Pearson; Andrew Berchuck; John T Soper
Journal:  Gynecol Oncol       Date:  2006-10-02       Impact factor: 5.482

4.  Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.

Authors:  Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

5.  Prognostic significance of gross myometrial invasion with endometrial cancer.

Authors:  D M Larson; G P Connor; S K Broste; B R Krawisz; K K Johnson
Journal:  Obstet Gynecol       Date:  1996-09       Impact factor: 7.661

6.  Clinical and pathologic correlates in surgical stage II endometrial carcinoma.

Authors:  David E Cohn; Emily M Woeste; Stacey Cacchio; Vanna L Zanagnolo; Laura J Havrilesky; Andrea Mariani; Karl C Podratz; Warner K Huh; Jenny M Whitworth; D Scott McMeekin; Matthew A Powell; Emily Boyd; Gary S Phillips; Jeffrey M Fowler
Journal:  Obstet Gynecol       Date:  2007-05       Impact factor: 7.661

7.  Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival.

Authors:  Nicholas C Lambrou; Orlando Gómez-Marín; Ramin Mirhashemi; Heather Beach; Emery Salom; Zoyla Almeida-Parra; Manuel Peñalver
Journal:  Gynecol Oncol       Date:  2004-06       Impact factor: 5.482

8.  Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  G F Fleming; V L Filiaci; R C Bentley; T Herzog; J Sorosky; L Vaccarello; H Gallion
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

9.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

Authors:  C P Morrow; B N Bundy; R J Kurman; W T Creasman; P Heller; H D Homesley; J E Graham
Journal:  Gynecol Oncol       Date:  1991-01       Impact factor: 5.482

10.  Brachytherapy: criteria for case selection.

Authors:  M E Randall; K M Greven
Journal:  Cancer Invest       Date:  1995       Impact factor: 2.176

View more
  6 in total

1.  Kaempferol, a natural dietary flavonoid, suppresses 17β-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer.

Authors:  Agapiti Hipoliti Chuwa; Kenbun Sone; Katsutoshi Oda; Michihiro Tanikawa; Asako Kukita; Machiko Kojima; Shinya Oki; Tomohiko Fukuda; Makoto Takeuchi; Aki Miyasaka; Tomoko Kashiyama; Yuji Ikeda; Kazunori Nagasaka; Mayuyo Mori-Uchino; Yoko Matsumoto; Osamu Wada-Hiraike; Hiroyuki Kuramoto; Kei Kawana; Yutaka Osuga; Tomoyuki Fujii
Journal:  Oncol Lett       Date:  2018-08-21       Impact factor: 2.967

2.  Usefulness of biopsy by office hysteroscopy for endometrial cancer: A case report.

Authors:  Kenbun Sone; Satoko Eguchi; Kayo Asada; Futaba Inoue; Yuichiro Miyamoto; Michihiro Tanikawa; Tetsushi Tsuruga; Mayuyo Mori-Uchino; Yoko Matsumoto; Osamu Hiraike-Wada; Katsutoshi Oda; Yutaka Osuga; Tomoyuki Fujii
Journal:  Mol Clin Oncol       Date:  2020-05-27

3.  Automated system for diagnosing endometrial cancer by adopting deep-learning technology in hysteroscopy.

Authors:  Yu Takahashi; Kenbun Sone; Katsuhiko Noda; Kaname Yoshida; Yusuke Toyohara; Kosuke Kato; Futaba Inoue; Asako Kukita; Ayumi Taguchi; Haruka Nishida; Yuichiro Miyamoto; Michihiro Tanikawa; Tetsushi Tsuruga; Takayuki Iriyama; Kazunori Nagasaka; Yoko Matsumoto; Yasushi Hirota; Osamu Hiraike-Wada; Katsutoshi Oda; Masanori Maruyama; Yutaka Osuga; Tomoyuki Fujii
Journal:  PLoS One       Date:  2021-03-31       Impact factor: 3.240

Review 4.  Machine Learning for Endometrial Cancer Prediction and Prognostication.

Authors:  Vipul Bhardwaj; Arundhiti Sharma; Snijesh Valiya Parambath; Ijaz Gul; Xi Zhang; Peter E Lobie; Peiwu Qin; Vijay Pandey
Journal:  Front Oncol       Date:  2022-07-27       Impact factor: 5.738

5.  Validated competing event model for the stage I-II endometrial cancer population.

Authors:  Ruben Carmona; Sachin Gulaya; James D Murphy; Brent S Rose; John Wu; Sonal Noticewala; Michael T McHale; Catheryn M Yashar; Florin Vaida; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

Review 6.  Pathogenesis and Clinical Management of Uterine Serous Carcinoma.

Authors:  Li Zhang; Suet Ying Kwan; Kwong Kwok Wong; Pamela T Solaman; Karen H Lu; Samuel C Mok
Journal:  Cancers (Basel)       Date:  2020-03-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.